中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 3
Mar.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(3): 683-689

Application of magnetic resonance elastography in assessment of liver fibrosis in metabolic dysfunction-associated fatty liver disease

DOI: 10.12449/JCH260325
  • 1.

    Liver Research Center，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

  • 2.

    State Key Laboratory of Digestive Health，National Clinical Research Center for Digestive Diseases，Beijing 100050，China

  • 3.

    Research Ward，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

Research funding:

National Natural Science Foundation of China (82400719);

Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZLRK202501);

Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZLRK202301)

More Information
  • Corresponding author: TONG Xiaofei， tongxf@163.com （ORCID： 0000-0001-9437-2937）
  • Received Date: 2025-07-25
  • Accepted Date: 2025-09-03
  • Published Date: 2026-03-25
    Abstract
  • Magnetic resonance elastography （MRE） has become an important tool for the diagnosis and staging of fibrosis in metabolic dysfunction-associated fatty liver disease （MAFLD）， and its high diagnostic accuracy can help to effectively evaluate the dynamic changes and long-term prognosis of fibrosis in patients with MAFLD. In addition， MRE also shows wide potential in patient screening and outcome assessment in new drug development for metabolic-associated steatohepatitis. This article comprehensively analyzes the potential value of MRE in evaluating liver fibrosis in MAFLD patients， as well as its advantages in clinical practice and future development directions.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    QUEK J, CHAN KE, WONG ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8( 1): 20- 30. DOI: 10.1016/S2468-1253(22)00317-X.
    [2]
    RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/HEP.0000000000000323.
    [3]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [4]
    European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD), European Association for the Study of Obesity(EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. J Hepatol, 2024, 81( 3): 492- 542. DOI: 10.1016/j.jhep.2024.04.031.
    [5]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.

    中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
    [6]
    SANYAL AJ, VAN NATTA ML, CLARK J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease[J]. N Engl J Med, 2021, 385( 17): 1559- 1569. DOI: 10.1056/NEJMoa2029349.
    [7]
    CHHATWAL J, DALGIC OO, CHEN WY, et al. Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2022, 5( 9): e2230426. DOI: 10.1001/jamanetworkopen.2022.30426.
    [8]
    PAI RK, JAIRATH V, HOGAN M, et al. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score[J]. Hepatology, 2022, 76( 4): 1150- 1163. DOI: 10.1002/hep.32475.
    [9]
    LIU ZY, ZHUANG YJ, DONG X, et al. Construction of a non-invasive diagnostic model for liver fibrosis in non-alcoholic fatty liver disease[J]. Clin J Med Offic, 2024, 52( 7): 688- 691. DOI: 10.16680/j.1671-3826.2024.07.07.

    刘正一, 庄颖洁, 董旭, 等. 非酒精性脂肪性肝病肝纤维化无创诊断模型构建[J]. 临床军医杂志, 2024, 52( 7): 688- 691. DOI: 10.16680/j.1671-3826.2024.07.07.
    [10]
    PEPIN KM, WELLE CL, GUGLIELMO FF, et al. Magnetic resonance elastography of the liver: Everything you need to know to get started[J]. Abdom Radiol, 2022, 47( 1): 94- 114. DOI: 10.1007/s00261-021-03324-0.
    [11]
    QIBA MR Biomarker Committee. Magnetic Resonance Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. P[EB/OL].( 2023-11-07)[ 2024-08-16]. https://qibawiki.rsna.org/images/4/47/MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf. https://qibawiki.rsna.org/images/4/47/MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf
    [12]
    SELVARAJ EA, MÓZES FE, JAYASWAL ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis[J]. J Hepatol, 2021, 75( 4): 770- 785. DOI: 10.1016/j.jhep.2021.04.044.
    [13]
    LIANG JX, AMPUERO J, NIU H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol, 2023, 79( 3): 592- 604. DOI: 10.1016/j.jhep.2023.04.025.
    [14]
    FURLAN A, TUBLIN ME, YU L, et al. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease[J]. AJR Am J Roentgenol, 2020, 214( 1): W20- W26. DOI: 10.2214/AJR.19.21267.
    [15]
    IMAJO K, HONDA Y, KOBAYASHI T, et al. Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2022, 20( 4): 908- 917. DOI: 10.1016/j.cgh.2020.12.016.
    [16]
    KIM MN, HAN JW, AN J, et al. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease[J]. Clin Mol Hepatol, 2024, 30( Suppl): S5- S105. DOI: 10.3350/cmh.2024.0506.
    [17]
    SIDDIQUI MS, VUPPALANCHI R, VAN NATTA ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2019, 17( 1): 156- 163. DOI: 10.1016/j.cgh.2018.04.043.
    [18]
    PARK CC, NGUYEN P, HERNANDEZ C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 3): 598- 607. DOI: 10.1053/j.gastro.2016.10.026.
    [19]
    CUI J, ANG B, HAUFE W, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: A prospective study[J]. Aliment Pharmacol Ther, 2015, 41( 12): 1271- 1280. DOI: 10.1111/apt.13196.
    [20]
    XIAO GQ, ZHU SX, XIAO X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis[J]. Hepatology, 2017, 66( 5): 1486- 1501. DOI: 10.1002/hep.29302.
    [21]
    NEWSOME PN, SASSO M, DEEKS JJ, et al. FibroScan-AST(FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 4): 362- 373. DOI: 10.1016/S2468-1253(19)30383-8.
    [22]
    NOUREDDIN M, TRUONG E, GORNBEIN JA, et al. MRI-based(MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol, 2022, 76( 4): 781- 787. DOI: 10.1016/j.jhep.2021.11.012.
    [23]
    STERLING RK, LISSEN E, CLUMECK N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology, 2006, 43( 6): 1317- 1325. DOI: 10.1002/hep.21178.
    [24]
    JUNG J, LOOMBA RR, IMAJO K, et al. MRE combined with FIB-4(MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis[J]. Gut, 2021, 70( 10): 1946- 1953. DOI: 10.1136/gutjnl-2020-322976.
    [25]
    KIM BK, TAMAKI N, IMAJO K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD[J]. J Hepatol, 2022, 77( 6): 1482- 1490. DOI: 10.1016/j.jhep.2022.07.020.
    [26]
    HAN MAT, VIPANI A, NOUREDDIN N, et al. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study[J]. Liver Int, 2020, 40( 9): 2242- 2251. DOI: 10.1111/liv.14593.
    [27]
    GIDENER T, AHMED OT, LARSON JJ, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD[J]. Clin Gastroenterol Hepatol, 2021, 19( 9): 1915- 1924. DOI: 10.1016/j.cgh.2020.09.044.
    [28]
    AJMERA VH, LIU A, SINGH S, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71( 3): 849- 860. DOI: 10.1002/hep.30974.
    [29]
    GIDENER T, DIERKHISING RA, MARA KC, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD[J]. Hepatology, 2023, 77( 1): 268- 274. DOI: 10.1002/hep.32594.
    [30]
    Food and Drug Administration. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: Developing drugs for treatment[EB/OL].( 2018-12-04)[ 2024-08-16]. https://www.federalregister.gov/documents/2018/12/04/2018-26333/noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment-draft. https://www.federalregister.gov/documents/2018/12/04/2018-26333/noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment-draft
    [31]
    National Medical Products Administration. Guidelines for clinical trials of drugs for treatment of nonalcoholic steatohepatitis(interim)[EB/OL].( 2019-12-20)[ 2024-08-16]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html

    国家药品监督管理局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则(试行)[EB/OL].( 2019-12-20)[ 2024-08-16]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html
    [32]
    CHEUNG A, NEUSCHWANDER-TETRI BA, KLEINER DE, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: Recommendations from the liver forum[J]. Hepatology, 2019, 70( 5): 1841- 1855. DOI: 10.1002/hep.30672.
    [33]
    WANG J, GLASER KJ, ZHANG TH, et al. Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients[J]. J Magn Reson Imaging, 2018, 47( 4): 976- 987. DOI: 10.1002/jmri.25818.
    [34]
    YIN ZY, MURPHY MC, LI JH, et al. Prediction of nonalcoholic fatty liver disease(NAFLD) activity score(NAS) with multiparametric hepatic magnetic resonance imaging and elastography[J]. Eur Radiol, 2019, 29( 11): 5823- 5831. DOI: 10.1007/s00330-019-06076-0.
    [35]
    ALLEN AM, SHAH VH, THERNEAU TM, et al. The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery[J]. Hepatology, 2020, 71( 2): 510- 521. DOI: 10.1002/hep.30483.
    [36]
    SHI Y, QI YF, LAN GY, et al. Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C[J]. Radiology, 2021, 301( 1): 154- 162. DOI: 10.1148/radiol.2021202804.
    [37]
    WU H, ZHU Z, LI JH, et al. Three-dimensional vector MR elastography for evaluating tissue mechanical heterogeneity to assess liver disease progression[J]. Radiology, 2025, 315( 1): e242349. DOI: 10.1148/radiol.242349.
    [38]
    LI MS, YANG H, LIU Y, et al. Comparison of the diagnostic performance of 2D and 3D MR elastography in staging liver fibrosis[J]. Eur Radiol, 2021, 31( 12): 9468- 9478. DOI: 10.1007/s00330-021-08053-y.
    [39]
    LU M, WANG MJ, CHEN L. Advances in the application of elastography in noninvasive diagnosis of liver fibrosis in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 2): 408- 412. DOI: 10.3969/j.issn.1001-5256.2023.02.025.

    陆梦, 王铭杰, 陈立. 弹性成像技术在非酒精性脂肪性肝病肝纤维化无创诊断中的应用进展[J]. 临床肝胆病杂志, 2023, 39( 2): 408- 412. DOI: 10.3969/j.issn.1001-5256.2023.02.025.
    [40]
    KIM DW, KIM SY, YOON HM, et al. Comparison of technical failure of MR elastography for measuring liver stiffness between gradient-recalled echo and spin-echo echo-planar imaging: A systematic review and meta-analysis[J]. J Magn Reson Imaging, 2020, 51( 4): 1086- 1102. DOI: 10.1002/jmri.26918.
    [41]
    GARTEISER P, DOBLAS S, van BEERS BE. Magnetic resonance elastography of liver and spleen: Methods and applications[J]. NMR Biomed, 2018, 31( 10): e3891. DOI: 10.1002/nbm.3891.
    [42]
    WANG K, MANNING P, SZEVERENYI N, et al. Repeatability and reproducibility of 2D and 3D hepatic MR elastography with rigid and flexible drivers at end-expiration and end-inspiration in healthy volunteers[J]. Abdom Radiol, 2017, 42( 12): 2843- 2854. DOI: 10.1007/s00261-017-1206-4.
    [43]
    BOYARKO AC, DILLMAN JR, TKACH JA, et al. Comparison of compressed SENSE and SENSE for quantitative liver MRI in children and young adults[J]. Abdom Radiol, 2021, 46( 10): 4567- 4575. DOI: 10.1007/s00261-021-03092-x.
    [44]
    DZYUBAK B, LI JH, CHEN J, et al. Automated analysis of multiparametric magnetic resonance imaging/magnetic resonance elastography exams for prediction of nonalcoholic steatohepatitis[J]. J Magn Reson Imaging, 2021, 54( 1): 122- 131. DOI: 10.1002/jmri.27549.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (27) PDF downloads(13) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return